Abstract:Protein kinase function and interactions with drugs are controlled in part by the movement of the DFG and ɑC-Helix motifs that are related to the catalytic activity of the kinase. Small molecule ligands elicit therapeutic effects with distinct selectivity profiles and residence times that often depend on the active or inactive kinase conformation(s) they bind. Modern AI-based structural modeling methods have the potential to expand upon the limited availability of experimentally determined kinase structures in inactive states. Here, we first explored the conformational space of kinases in the PDB and models generated by AlphaFold2 (AF2) and ESMFold, two prominent AI-based protein structure prediction methods. Our investigation of AF2's ability to explore the conformational diversity of the kinome at various multiple sequence alignment (MSA) depths showed a bias within the predicted structures of kinases in DFG-in conformations, particularly those controlled by the DFG motif, based on their overabundance in the PDB. We demonstrate that predicting kinase structures using AF2 at lower MSA depths explored these alternative conformations more extensively, including identifying previously unobserved conformations for 398 kinases. Ligand enrichment analyses for 23 kinases showed that, on average, docked models distinguished between active molecules and decoys better than random (average AUC (avgAUC) of 64.58), but select models perform well (e.g., avgAUCs for PTK2 and JAK2 were 79.28 and 80.16, respectively). Further analysis explained the ligand enrichment discrepancy between low- and high-performing kinase models as binding site occlusions that would preclude docking. The overall results of our analyses suggested that, although AF2 explored previously uncharted regions of the kinase conformational space and select models exhibited enrichment scores suitable for rational drug discovery, rigorous refinement of AF2 models is likely still necessary for drug discovery campaigns.

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

Predicting Inactive Conformations Of Protein Kinases Using Active Structures: Conformational Selection Of Type-Ii Inhibitors

Revealing the Favorable Dissociation Pathway of Type II Kinase Inhibitors Via Enhanced Sampling Simulations and Two-End-state Calculations

Revealing the Unbinding Kinetics and Mechanism of Type I and Type II Protein Kinase Inhibitors by Local-Scaled Molecular Dynamics Simulations

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Overcoming Secondary Mutations of Type II Kinase Inhibitors

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Comprehensive Assessment of Nine Docking Programs on Type II Kinase Inhibitors: Prediction Accuracy of Sampling Power, Scoring Power and Screening Power.

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Targeting cancer with small molecule kinase inhibitors

Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

Using the Structural Kinome to Systematize Kinase Drug Discovery